Current Management of Refractory Germ Cell Tumors and Future Directions

Late Relapses in Stage I Testicular Cancer Patients on Surveillance

(2016) Mette Saksø Mortensen et al.   EUROPEAN UROLOGY

Phase II study of everolimus in refractory testicular germ cell tumors

(2016) Michal Mego et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Testicular Cancer: A Reflection on 50 Years of Discovery

(2014) Nasser Hanna et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Clinical Trial of Oxaliplatin and Bevacizumab in Refractory Germ Cell Tumors

(2013) Amit Jain et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Combination of Paclitaxel, Cisplatin, and Gemcitabine (TPG) for Multiple Relapses or Platinum-Resistant Germ Cell Tumors: Long-Term Outcomes

(2013) Andrea Necchi et al.   Clinical Genitourinary Cancer

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors

(2013) Darren R. Feldman et al.   INVESTIGATIONAL NEW DRUGS

Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial

(2012) Darren R. Feldman et al.   Journal of Cancer

Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study

(2011) K. Oechsle et al.   ANNALS OF ONCOLOGY

Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database

(2011) Anja Lorch et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)

(2010) G. Daugaard et al.   ANNALS OF ONCOLOGY

Non–Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital’s Experience

(2010) Jeremy F. Sturgeon et al.   EUROPEAN UROLOGY

Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy

(2010)   JOURNAL OF CLINICAL ONCOLOGY

High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors

(2009) A. Lorch et al.   ANNALS OF ONCOLOGY

Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy

(2009) C. Kollmannsberger et al.   ANNALS OF ONCOLOGY

Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours

(2009) Nicola Nicolai et al.   BJU INTERNATIONAL

Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors

(2009) Darren R. Feldman et al.   INVESTIGATIONAL NEW DRUGS

Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program

(2009) Torgrim Tandstad et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP

(2008) Stéphane Culine et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Outcome and Predictors of Survival in Late Relapse of Germ Cell Tumor

(2008) David S. Sharp et al.   JOURNAL OF CLINICAL ONCOLOGY